Venn Life Sciences has joined the Irish Stock Exchange's Enterprise Securities Market (ESM).
The company provides drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. It has a market capitalisation of €19m.
Venn has operations in France, Germany, the Netherlands, the UK and Ireland, and it also has people worldwide working on clinical studies for the company.
The company said it is utilising the ESM's dual listing regime with the London Stock Exchange's AIM to enable Irish and international investors access their shares.
It joins other ISE listings operating in the pharmaceutical and biotechnology sectors - Malin Corporation, Mainstay Medical and Merrion Pharmaceuticals.
"Joining the Enterprise Securities Market was an easy decision for us. Given our existing listing on AIM, the process to add an ESM quotation was very straightforward," commented the company's chief executive Tony Richardson.
"Having a euro quotation through the ISE will enable us to expand our investor base by accessing both euro and sterling pools of capital and facilitate future growth," he added.
